Aktis OncologyAKTS -5.49%9 Altman Z-Score is 14.16 as of Jun. 28, 2026, which is 61% above its 10-year median of 8.78. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 3 warning signs investors should review. Among 933 Biotechnology companies, Aktis Oncology ranks better than 82.74% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 14.16 is strong.
Aktis Oncology has a Altman Z-Score of 14.16, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Aktis Oncology's Altman Z-Score or its related term are showing as below:
AKTS'
s Altman Z-Score Range Over the Past 10 Years
Min: 8.78 Med: 8.78 Max: 14.16
Current: 14.16
During the past 4 years, Aktis Oncology's highest Altman Z-Score was 14.16. The lowest was 8.78. And the median was 8.78.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Aktis Oncology Altman Z-Score Related Terms
Aktis Oncology Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Aktis Oncology's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AKTS vs OLMA, EYPT, ZBIO: Altman Z-Score Comparison
For the Biotechnology subindustry, Aktis Oncology's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aktis Oncology Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aktis Oncology's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Aktis Oncology's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Aktis Oncology's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.8946
+
1.4
*
-0.3032
+
3.3
*
-0.084
+
0.6
*
22.9655
+
1.0
*
0.0113
=
14.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Aktis Oncology (AKTS) has a Altman Z-Score of 14.16 as of Jun. 28, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Aktis Oncology and its competitors. This is 61% above median its historical median of 8.78. Over the past decade, Aktis Oncology's Altman Z-Score has ranged from 8.78 to 14.16. According to the industry distribution chart, Aktis Oncology ranks #161 out of 933 companies in the Biotechnology industry, placing it in the top 17.3%.
Is Aktis Oncology's Altman Z-Score too high?
Aktis Oncology's current Altman Z-Score of 14.16 is 61% above median its 10-year median of 8.78. Over the past 10 years, this metric has ranged from a low of 8.78 to a high of 14.16. The Biotechnology industry median Altman Z-Score is 2.55. Aktis Oncology's value of 14.16 is 455.3% above this industry median. Based on the distribution chart, Aktis Oncology ranks #161 out of 933 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Altman Z-Score compare to OLMA and EYPT?
According to the Biotechnology industry distribution chart, Aktis Oncology ranks #161 out of 933 companies for Altman Z-Score. This places Aktis Oncology in the top 17% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.55. Aktis Oncology's value of 14.16 is 455.3% above this benchmark. Historically, Aktis Oncology's own Altman Z-Score has ranged from 8.78 to 14.16 over the past decade. While the company's 10-year median is 8.78 vs. the industry median of 2.55, Aktis Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.55, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aktis Oncology's current Altman Z-Score of 14.16 is 455.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Aktis Oncology and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aktis Oncology's current Altman Z-Score is 14.16, which is 61% above median its own 10-year median of 8.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Altman Z-Score of 14.16. The current Altman Z-Score is 14.16, which is 61% above median its 10-year median of 8.78 and 455.3% above the Biotechnology industry median of 2.55. Aktis Oncology's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Altman Z-Score is 14.16 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score
Get the complete analysis for AKTS
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKTS has been successfully added to your 